Press Release Archive - R&D News

R&D News

01.13.2004
Namenda(TM) (memantine HCl), First Drug Approved For Treatment of Moderate to Severe Alzheimer's Disease Now Available Nationwide
01.07.2004
Namenda(TM) (Memantine HCl) Mild to Moderate Alzheimer's Disease Studies Reported Today Forest Laboratories to Seek Approval for Mild to Moderate Indication By Mid-Year
12.18.2003
Lexapro(TM) Receives FDA Approval for the Treatment of Generalized Anxiety Disorder
12.10.2003
Starting Dose of Lexapro(TM) as Effective as Optimally Dosed Zoloft(R) in the Treatment of Major Depressive Disorder
11.12.2003
Long-Term Treatment With Aerospan(TM) Has No Effect On Growth In Children With Mild Asthma
10.22.2003
Forest Laboratories to Resume Clinical Development of Neuropathic Pain Indication for Memantine
10.17.2003
FDA Approves Namenda(TM) (memantine HCl) for the Treatment of Moderate to Severe Alzheimer's Disease
10.01.2003
Forest to Discontinue Development in U.S. of Dexloxiglumide for Irritable Bowel Syndrome (IBS)
09.29.2003
Lexapro(TM) Receives FDA Approvable Letter for the Treatment of Generalized Anxiety Disorder (GAD)
09.24.2003
FDA Advisory Committee Unanimously Votes That Data Submitted Supports Safety and Efficacy of Namenda(TM) (Memantine HCl) For Moderate to Severe Alzheimer's Disease